HEALTH INTEROPERABILITYREVIEW

Move data. Preserve meaning. Prove the exchange.

Product Intelligence · Implementation-guide analysis

CARIN Blue Button 2.2 updates the consumer claims-data implementation layer

The current guide provides a sharper reference for consumer-directed claims exchange, while payer obligations and production readiness still require separate verification.

Editorial figure by Health Interoperability Review. Source context: HL7 International.

A guide version is only one layer of readiness

Payer API programs combine FHIR profiles with identity proofing, authorization, member matching, developer onboarding, traffic controls, privacy notices, support operations, and source-system extraction. A platform can implement the guide while the broader operating program remains incomplete.

Comparisons should identify which layer a provider supplies. Some vendors deliver API infrastructure, others add payer-domain mapping and operations, and others focus on consumer applications or network connectivity. Those models are adjacent, not interchangeable.

Evidence should follow the member journey

A practical test begins with app registration and authorization, follows identity and coverage matching, retrieves representative claims data, and evaluates terminology, timeliness, completeness, revocation, error handling, and support. Static endpoint documentation cannot demonstrate that full path.

Procurement teams should request version-specific conformance artifacts plus production operating measures. They should record dependencies on plan systems, PBMs, delegated entities, clearinghouses, and data partners outside the platform's direct control.

Enterprise buyer test

Translate this change into the exact population, record type, workflow stage, decision owner, effective date, and evidence that could be affected. Ask current or prospective providers to demonstrate the named workflow with representative data and an exception—not a polished feature tour. Record what official documentation establishes, what a provider states, what the team observes, and what remains unresolved.

A defensible review also identifies the dependency outside the product. Authority interpretation, policy configuration, data quality, integrations, human judgment, approval rights, release governance, training, and retained evidence may remain customer or service responsibilities. The evaluation should preserve those boundaries instead of treating a technology claim as the complete operating model.

What we will watch next

Health Interoperability Review will watch the named source and affected market records for later evidence that changes status, scope, availability, implementation timing, workflow consequence, or the limits of the initial report. A later announcement does not silently overwrite this dated account; the change ledger preserves the sequence.

Primary source: HL7 International · Standards publication.

Evidence boundary: Independent analysis of an HL7 publication. This does not provide coverage, clinical, legal, certification, or implementation advice.

Editorial record: Published March 27, 2026; updated July 19, 2026. Corrections policy.

Related organizations

Explore all